Chongqing Lummy Pharmaceutical Co., Ltd. (300006) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chongqing Lummy Pharmaceutical Co., Ltd.

Why is Chongqing Lummy Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of -13.87% and Operating profit at -0.16% over the last 5 years

Negative results in Sep 25

NET PROFIT(HY) At CNY -32.14 MM has Grown at -47.16%
OPERATING CASH FLOW(Y) Lowest at CNY 42.81 MM
NET SALES(HY) At CNY 379.23 MM has Grown at -10.67%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 19.09%, its profits have fallen by -290.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Chongqing Lummy Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Chongqing Lummy Pharmaceutical Co., Ltd.

19.09%

1.66

47.79%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.87%

EBIT Growth (5y)

-0.16%

EBIT to Interest (avg)

-8.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.27

Sales to Capital Employed (avg)

0.36

Tax Ratio

2.21%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.46

EV to EBIT

-27.42

EV to EBITDA

-43.13

EV to Capital Employed

3.09

EV to Sales

5.14

PEG Ratio

Dividend Yield

ROCE (Latest)

-11.28%

ROE (Latest)

-6.36%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

NET PROFIT(HY)

Higher at CNY -32.14 MM

RAW MATERIAL COST(Y)

Fallen by 1.17% (YoY

CASH AND EQV(HY)

Highest at CNY 2,025.53 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.94 times

DEBTORS TURNOVER RATIO(HY)

Highest at 1.71 times

-25What is not working for the Company

NET PROFIT(HY)

At CNY -32.14 MM has Grown at -47.16%

OPERATING CASH FLOW(Y)

Lowest at CNY 42.81 MM

NET SALES(HY)

At CNY 379.23 MM has Grown at -10.67%

ROCE(HY)

Lowest at -5.51%

INTEREST(Q)

Highest at CNY 3.74 MM

Here's what is working for Chongqing Lummy Pharmaceutical Co., Ltd.

Net Profit

Higher at CNY -32.14 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Cash and Eqv

Highest at CNY 2,025.53 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 1.94 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 1.71 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 1.17% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Chongqing Lummy Pharmaceutical Co., Ltd.

Net Profit

At CNY -32.14 MM has Grown at -47.16%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Interest

At CNY 3.74 MM has Grown at 22.01%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 379.23 MM has Grown at -10.67%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Cash Flow

Lowest at CNY 42.81 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

Highest at CNY 3.74 MM

in the last five periods and Increased by 22.01% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)